Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy Beagles

American Journal of Veterinary Research

Volumn 58, Issue 5, 1997, Pages 504-510

  Bartges, Joseph W ^a,c   Osborne, Carl A ^a   Felice, Lawrence J ^a,d   Koehler, Lori A ^a   Ulrich, Lisa K ^a   Bird, Kathy A ^a   Chen, Menglan ^a   Sawchuk, Ronald J ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d MEDTOX Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; DRUG METABOLITE; OXIPURINOL; URIC ACID; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DOG; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ALLOPURINOL; ANIMALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; INJECTIONS, INTRAVENOUS; OXYPURINOL;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031008261     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Osborne CA, Lulich JP, Unger LK, et al. Canine and feline urolithiasis: relationship of etiopathogenesis to treatment and prevention. In: Bojrab MJ, ed. Disease mechanisms in small animal surgery. Philadelphia: Lea & Febiger, 1992;464-511.
2. Ling GV, Ruby AL, Harrold DR, et al. Xanthine-containing urinary calculi in dogs given allopurinol. J Am Vet Med Assoc 1991; 198:1935-1940.
3. Reiter S, Simmonds HA, Webster DR, et al. On the metabolism of allopurinol: formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharm 1983;32:2167-2174.
4. Elion GB. Allopurinol and other inhibitors of urate synthesis. In: Kelley WN, Weiner IM, ed. Handbook of experimental pharmacology. Volume 51, uric acid. Berlin: Verlag-Springer, 1978;475-514.
5. Elion GB, Kovensky A, Hitchings GH, et al. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharm 1966;15:863-880.
6. Koch-Weser J. Bioavailability of drugs: part I. N Engl J Med 1974;291:233-237.
7. Applebaum SJ, Mayersohn M, Dorr RT, et al. Allopurinol kinetics and bioavailability. Intravenous, oral, and rectal administration. Cancer Chemother Pharmacol 1982;14:93-98.
8. Bartges JW, Osborne CA, Felice LJ, et al. Influence of allopurinol and two diets on 24-hour urinary excretions of uric acid, xanthine, and ammonia by healthy dogs. Am J Vet Res 1995;56:595-599.
9. Bartges JW, Osborne CA, Felice LJ, et al. Diet effect on activity product ratios of uric acid, sodium urate, and ammonium urate in urine formed by healthy Beagles. Am J Vet Res 1995;56:329-333.
10. Bartges JW, Osborne CA, Felice LJ, et al. Influence of two amounts of dietary casein on uric acid, sodium urate, and ammonium urate urinary activity product ratios of healthy Beagles. Am J Vet Res 1995;56:893-897.
11. Bartges JW, Osborne CA, Felice LJ, et al. Influence of four diets containing approximately 11% protein (dry weight) on uric acid, sodium urate, and ammonium urate urine activity product ratios of healthy Beagles. Am J Vet Res 1995;56:60-65.
12. Osborne CA, Stevens JB. Handbook of canine and feline urinalysis. St Louis: Ralston Purina, 1981.
13. Center SA, Baldwin BH, Erb HN, et al. Bile acid concentrations in the diagnosis of hepatobiliary disease in the dog. J Am Vet Med Assoc 1985;187:935-940.
14. National Institutes of Health. Guide for the care and use of laboratory animals. NIH publication No. 85-23. Washington, DC: National Institutes of Health, 1985.
15. Laging C, Pospischil A, Giesecke D. Peroxisomen in leber und nieren von hunden bei purinreicher and purinarmer ernahrung. Zentralbl Veterinarmed [A] 1988;35:285-290.
16. Haskins SC. Fluid and electrolyte therapy. Compend Contin Educ Pract Vet 1984;6:244-260.
17. Pocock SJ. Clinical trials. Chichester, NY: John Wiley & Sons, 1989;110-122.
18. Bartges JW, Osborne CA, Felice LJ. Canine xanthine uroliths: risk factor management. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Philadelphia: WB Saunders Co, 1992;900-905.
19. Senior DF. Medical management of urate uroliths. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders Co. 1989;1178-1181.
20. Johnson EL, Reynolds DL, Wright DS, et al. Biological sample preparation and data reduction concepts in pharmaceutical analysis. J Chromatogr Sci 1988;20:372-379.
21. Baggot JD. Principles of drug disposition in domestic animals. Philadelphia: WB Saunders Co, 1977;145-189.
22. DiStefano JJI, Landaw EM. Multiexponential, multicompartmental, and noncompartmental modeling I. Methodological limitations and physiological interpretations. Am J Physiol 1984;246: R651-R664.
23. Devore J, Peck R. Statistics: the exploration and analysis of data. St Paul: West Publishing Co, 1986;411-439.
24. Nelson DJ, Elion GB. Metabolic studies of high doses of allopurinol in humans. In: De Bruyn CHMM, Simmonds HA, Muller M, eds. Purine metabolism in man-IV, part A. New York: Plenum Press, 1984;167-170.
25. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution, and physiology. Acta Physiol Scand 1986;Suppl 548:87-99.
26. Rowland M, Tozer TN. Clinical pharmacokinetics. Philadelphia: Lea & Febiger, 1989;376-400.
27. Elion GB. Enzymatic and metabolic studies with allopurinol. Ann Rheum Dis 1996;25:608-614.
28. Murrell GAC, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokin 1986;11:343-353.
29. Murata K, Noda K, Kohno K, et al. Pharmacokinetics analysis of concentration data of drugs with irregular absorption profiles using multifraction absorption models. J Pharm Sci 1987;76:109-113.
30. Marcus M, Tse FLS, Kleinberg SI. The bioavailability of two commercial preparations of allopurinol tablets. In J Clin Pharm Ther Tox 1982;20:302-305.
31. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharm Ther 1978;23:598-605.